Selank vs Semax: Neuropeptide Mechanism Comparison

TL;DR: Selank and Semax are both synthetic heptapeptides developed in Russia, but they derive from structurally unrelated parent compounds and engage distinct primary mechanisms. Selank is an analog of the immunomodulatory tetrapeptide tuftsin, documented in preclinical models for GABAergic allosteric modulation and anxiolytic-like activity. Semax is an analog of the ACTH(4-10) hormonal fragment, documented principally for upregulation of BDNF and NGF expression in the rat brain and neuroprotective effects in cerebral ischemia models. Both compounds show BDNF involvement in rodent studies, a meaningful point of overlap, but differ sharply in structural origin, primary receptor pharmacology, and the breadth of their published preclinical research. Neither is FDA approved. Both have Russian regulatory registration. The evidence base for each is concentrated in Russian academic institutions and is limited by international replication standards.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Selank and Semax are research compounds not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

Selank vs Semax: Quick Comparison at a Glance

The table below summarizes the primary documented distinctions between Selank and Semax based on published peer-reviewed literature. This is a mechanism reference, not a clinical or therapeutic comparison.

What Is Selank? Structure and Primary Mechanism

Selank (also designated TP-7) has the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a metabolically stabilized derivative of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) cleaved from immunoglobulin G and known for macrophage activation and immune modulation. The Pro-Gly-Pro C-terminal extension was added specifically to resist the serum enzymatic degradation that rapidly limits native tuftsin’s in vivo half-life.

For a deeper profile of Selank’s mechanisms, structure, and evidence tier, see the standalone compound post: What Is Selank? Mechanism and Evidence.

Selank’s GABAergic Mechanism: What the Research Documents

The most directly characterized molecular mechanism of Selank involves positive allosteric modulation of GABA-A receptors. According to PubMed-indexed research, a 2018 radioligand-receptor study by Vyunova et al., published in Protein and Peptide Letters, demonstrated that Selank modulates [³H]GABA binding in rat brain membrane preparations in a concentration-dependent, subtype-selective manner consistent with positive allosteric modulation. The joint effect of Selank with benzodiazepines (diazepam and olanzapine) was non-cumulative and distinct from either compound alone, suggesting partially overlapping but non-identical binding sites. The investigators concluded that allosteric GABA-A modulation represents one of Selank’s primary anti-anxiety molecular mechanisms (PMID 30255741).

Supporting this GABAergic hypothesis at the gene-expression level, a 2016 study by Volkova et al., published in Frontiers in Pharmacology, used real-time PCR to analyze 84 neurotransmission-related genes in rat frontal cortex 1 and 3 hours after Selank administration. Significant changes were observed in 45 genes at 1 hour, with a positive correlation between Selank and GABA on gene expression patterns, findings the authors interpreted as consistent with GABAergic allosteric modulation (PMID 26924987).

Selank and BDNF: A Secondary but Documented Pathway

BDNF modulation is not Selank’s primary mechanistic characterization, but it has been documented in rodent models. Based on PubMed-indexed research, Inozemtseva et al. (2008), published in Doklady Biological Sciences, administered Selank intranasally to male Wistar rats and used RT-PCR and immunoenzymatic assay to measure BDNF mRNA and protein in the hippocampus in vivo, documenting that intranasal Selank produced changes in hippocampal BDNF expression (PMID 18841804). This positions BDNF as a secondary downstream feature of Selank’s mechanistic profile, relevant to the overlap discussion with Semax but not its primary pharmacological identifier.

Selank and Anxiolytic-Like Activity in Behavioral Models

Consistent with its GABAergic mechanistic profile, Selank has been evaluated in multiple rodent behavioral paradigms for anxiolytic-like activity. A 2014 study by Kolik et al. in the Bulletin of Experimental Biology and Medicine documented that a single intraperitoneal injection of Selank (0.3 mg/kg) eliminated anxiety-like behavior induced by ethanol withdrawal in alcohol-preferring rats in the elevated plus maze and social interaction tests, without affecting ethanol consumption (PMID 24913576). A 2022 study by Konstantinopolsky et al. in the same journal found that the same Selank dose reduced the total index of naloxone-precipitated morphine withdrawal syndrome by approximately 40% in morphine-dependent rats, attenuating convulsive reactions, ptosis, and postural disorders, effects described as directionally comparable to, though slightly weaker than, diazepam at 2 mg/kg (PMID 36322304). These behavioral findings are consistent with the compound’s documented GABAergic mechanism but do not establish human efficacy for any condition.

What Is Semax? Structure and Primary Mechanism

Semax has the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a synthetic analog of the N-terminal fragment spanning positions 4 through 10 of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), with a Pro-Gly-Pro C-terminal extension added for the same reason as in Selank: to confer metabolic stability in biological fluids. Despite its ACTH-derived sequence, Semax is described consistently in the published literature as “completely devoid of any hormonal activity, ” distinguishing it from ACTH itself.

Semax was developed primarily by Nikolay Myasoedov and colleagues at the Institute of Molecular Genetics, Russian Academy of Sciences. It has been registered for clinical use in Russia and studied in that context for stroke rehabilitation. For a detailed standalone profile, see: What Is Semax? Mechanism and Evidence.

Semax’s BDNF and Neurotrophin Mechanism: What the Research Shows

The most replicated and best-characterized mechanistic finding for Semax is upregulation of brain-derived neurotrophic factor (BDNF) expression in the rat brain following intranasal administration. Based on PubMed-indexed research, Dolotov et al. (2006), published in Brain Research, documented that a single intranasal Semax application (50 µg/kg) produced a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and a 3-fold increase in exon III BDNF mRNA levels in the rat hippocampus. Semax-treated animals also showed increased conditioned avoidance reactions. The authors concluded that Semax affects cognitive brain functions by modulating hippocampal BDNF/trkB system expression and activation (PMID 16996037).

A companion 2006 study by the same group, published in the Journal of Neurochemistry, identified specific, reversible Semax binding sites on cell membranes isolated from rat basal forebrain (KD 2.4 ± 1.0 nM), and showed that intranasal Semax at 50 and 250 µg/kg produced rapid increases in BDNF protein in the basal forebrain at 3 hours post-application, without significant effects in the cerebellum, indicating region-specific activity (PMID 16635254).

Beyond BDNF, Agapova et al. (2007), published in Neuroscience Letters, documented that Semax (50 µg/kg, single intranasal application) induced rapid, gene- and region-specific changes in both BDNF and nerve growth factor (NGF) expression in intact rat brain: BDNF expression increased in hippocampus, brainstem, and cerebellum, while NGF decreased in the frontal cortex, a profile the authors characterized as selective rather than globally stimulatory (PMID 17353092).

Semax in Cerebral Ischemia Models

A distinct research strand in the Semax literature, absent in Selank’s profile, concerns neuroprotection in rodent cerebral ischemia models. Dmitrieva et al. (2009), published in Cellular and Molecular Neurobiology, examined neurotrophin and receptor gene expression following permanent middle cerebral artery occlusion in rats. Semax selectively activated transcription of BDNF, NT-3, and NGF, as well as their Trk receptors, in the ischemic rat cortex at 3, 24, and 72 hours after occlusion, a profile the authors characterized as distinct from the non-selective effects of the PGP tripeptide alone (PMID 19633950). This ischemia-model literature forms the preclinical basis for Semax’s Russian clinical registration for stroke rehabilitation.

How Do Selank and Semax Differ, and Where Do They Overlap?

The Core Mechanistic Divergence

Selank and Semax occupy distinct positions in the neuropeptide pharmacology literature despite their superficial similarities, both are synthetic Russian heptapeptides with C-terminal Pro-Gly-Pro extensions and overlapping institutional origins. The fundamental divergence is mechanistic and structural:

Selank’s primary documented pathway in rodent models is inhibitory neurotransmission modulation, specifically, positive allosteric modulation of GABA-A receptors, the same receptor family targeted by benzodiazepines. Its pharmacological comparators in the literature are diazepam and other classical anxiolytics. Its behavioral profile in rodent models is consistent with anxiolytic-like activity, not cognitive enhancement as a primary readout.

Semax’s primary documented pathway is neurotrophic signaling, specifically, upregulation of BDNF and NGF gene and protein expression in multiple brain regions following intranasal administration. Its pharmacological context in the literature is neuroprotection and cognitive facilitation, particularly in ischemia models and memory paradigms. Its behavioral comparators include piracetam and other nootropic agents, not benzodiazepines.

The BDNF Overlap: Real but Asymmetric

Both compounds have documented interactions with BDNF in rodent models, this is a genuine, not superficial, overlap. However, the nature and centrality of this overlap differ significantly between the two compounds. For Semax, BDNF upregulation is the primary and most replicated mechanistic finding across multiple independent studies. For Selank, BDNF modulation appears as a secondary, less-extensively-characterized finding documented in fewer publications, with the primary mechanism assigned to GABAergic allosteric modulation.

The shared Pro-Gly-Pro C-terminal extension is likely relevant: this tripeptide has been independently documented to have biological activity in the CNS context (Dmitrieva et al., 2009 compared Semax and PGP directly), and Selank’s metabolic fragments have also been studied for biological activity (Andreeva et al., 2010). Both compounds may share some downstream neurobiological consequences through this shared structural fragment, even though their primary parent sequences are unrelated.

Immunomodulation: Selank-Specific

One dimension of Selank’s profile that has no parallel in the Semax literature is immunomodulation. Selank’s structural derivation from tuftsin, an endogenous tetrapeptide with well-documented macrophage-stimulating and immunomodulatory functions, gives it a documented immunological dimension. Studies have examined changes in cytokine and chemokine gene expression following Selank administration in mouse models (Kolomin et al., 2011, PMID 21786679). This pathway is not a feature of Semax’s documented mechanistic profile.

Evidence Tier Comparison: An Honest Assessment

Both compounds share important structural limitations in their evidence bases that should be stated plainly. The table below summarizes the evidence landscape for each compound.

Critical limitation to state plainly: Both compounds share the same structural epistemic constraint, the published research is heavily concentrated within a small number of Russian academic institutions, primarily the Institute of Molecular Genetics and the V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Sciences. This is not evidence of fraudulent research, but it does mean that independent replication by unaffiliated Western laboratories is minimal. Rodent behavioral models of anxiety-like activity and ischemia-based neuroprotection do not reliably predict human clinical outcomes. The mechanistic findings described above are scientifically documented observations in experimental systems; they do not establish human efficacy or safety for either compound. The honest summary is that both compounds are interesting research subjects with coherent mechanistic profiles at the preclinical level, but their clinical potential in humans remains scientifically unestablished by Western evidence standards.

Regulatory Status: Both Compounds

United States (FDA)

Neither Selank nor Semax is approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. Neither has an approved human therapeutic indication, approved dosing protocol, or legal availability as a pharmaceutical in the United States. Both are classified as research compounds. Researchers should consult current FDA guidance directly.

Russia

Selank is registered in Russia as a pharmaceutical drug in nasal drops formulation for use as an anxiolytic. Semax is registered in Russia for clinical use in neurological indications, including stroke rehabilitation. These registrations reflect the regulatory framework of the Russian Ministry of Health and do not confer approval status in the United States, European Union, or other Western regulatory jurisdictions. Primary registration data for either compound is not widely accessible in the English-language literature.

Frequently Asked Questions

What is the core difference between Selank and Semax?

Do both Selank and Semax affect BDNF?

Yes, BDNF modulation is a documented point of overlap. Selank has been shown to regulate hippocampal BDNF expression following intranasal administration in rats (Inozemtseva et al., 2008; PMID 18841804). Semax’s BDNF upregulation is more extensively studied and represents its primary mechanistic characterization: a single intranasal application documented a 1.4-fold increase in hippocampal BDNF protein and a 3-fold increase in BDNF mRNA (Dolotov et al., 2006; PMID 16996037). The overlap is real but asymmetric, for Semax, BDNF upregulation is the central finding; for Selank, it is secondary to the GABAergic mechanism.

Are Selank and Semax FDA approved?

No. Neither compound is approved by the U.S. Food and Drug Administration for any therapeutic use in humans. Both are registered in Russia under different regulatory standards. Neither holds FDA or EMA approval. Both are classified as research compounds in the United States.

Where can evidence tiers for both compounds be reviewed in full?

For educational and research reference purposes only. Not medical advice. Not for human use.